Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.
Approval Alert | Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
4
BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer
5
